Melanoma, lymphoma: Compound active against genetic mutation cancer
Chapel Hill, NC – In a step forward in the push for targeted treatments that can block the specific molecular malfunctions driving cancer, University of North Carolina Lineberger Comprehensive Cancer Center researchers have demonstrated how a genetic mutation can drive the most common type of lymphoma as well as melanoma, the deadliest form of skin cancer.
The researchers reported in Nature Medicine today the description of new laboratory models of B-cell lymphoma and melanoma featuring a specific mutation of EZH2, a gene known to regulate cell fate. The authors also demonstrated that a new investigational inhibitor, JQEZ5, blocked the function of the protein made by the EZH2 gene, and that it was highly active in EZH2-driven cancer models.
“We have shown that the biology of tumors driven by this mutation is distinct from other types of lymphoma and melanoma, and that these tumors require persistent malfunction of EZH2 for growth,” said Norman Sharpless, MD, director of UNC Lineberger and the Wellcome Distinguished Professor of Cancer Research. “And with our collaborators, we have shown that a potential new drug designed to target EZH2 mutations in such cancers is very active in our laboratory models.” Continue>
Posted in: Specialties | August 21, 2015
Posted in: Specialties | November 18, 2014
Posted in: Specialties | July 2, 2013